Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is tanezumab more effective than a placebo in reducing pain in patients with osteoarthritis?”

STUDY DESIGN: Review of three randomized, double-blind, placebo controlled trials from 2012 to 2015.

DATA SOURCES: Three double-blind randomized clinical trials (RCTs) were found using PubMed, and selected based on outcomes measured and relevance to the objective.

OUTCOMES MEASURED: Clinical outcomes of knee and hip osteoarthritis pain were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale to assess pain before and after treatment with tanezumab and comparison.

RESULTS: All three randomized studies showed treatment with tanezumab was statistically significant (p-value ≤0.001) for improvement in pain at 16 weeks after injections. An adverse event was reported in each study.

CONCLUSIONS: Based on the studies reviewed in this paper, the evidence suggest the efficacy of tanezumab for hip and knee osteoarthritis pain is conclusive as an effective treatment.